231 related articles for article (PubMed ID: 25728057)
1. Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.
O'Neill CB; Baxi SS; Atoria CL; O'Neill JP; Henman MC; Sherman EJ; Lee NY; Pfister DG; Elkin EB
Cancer; 2015 Jun; 121(12):2083-9. PubMed ID: 25728057
[TBL] [Abstract][Full Text] [Related]
2. Toxicity after adjuvant therapy for stage III uterine cancer.
Chen LC; Huang Y; Hou JY; Khoury-Collado F; Melamed A; St Clair CM; Tergas AI; Hur C; Hillyer GC; Hershman DL; Wright JD
Gynecol Oncol; 2020 Dec; 159(3):737-743. PubMed ID: 33008633
[TBL] [Abstract][Full Text] [Related]
3. Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis.
Beadle BM; Liao KP; Giordano SH; Garden AS; Hutcheson KA; Lai SY; Guadagnolo BA
Cancer; 2017 Jan; 123(2):283-293. PubMed ID: 27662641
[TBL] [Abstract][Full Text] [Related]
4. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma.
Lavaf A; Genden EM; Cesaretti JA; Packer S; Kao J
Cancer; 2008 Feb; 112(3):535-43. PubMed ID: 18076014
[TBL] [Abstract][Full Text] [Related]
6. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.
Sher DJ; Neville BA; Chen AB; Schrag D
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e197-206. PubMed ID: 21596483
[TBL] [Abstract][Full Text] [Related]
7. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
8. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.
Noronha V; Sharma V; Joshi A; Patil VM; Laskar SG; Prabhash K
Indian J Cancer; 2017; 54(2):453-457. PubMed ID: 29469077
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
12. Late toxicity after radical treatment for locally advanced head and neck cancer.
Taberna M; Rullan AJ; Hierro C; Navarro V; Vázquez S; Lozano A; Vilajosana E; Maños M; Marí A; Viñals J; Mesía R
Oral Oncol; 2015 Aug; 51(8):795-9. PubMed ID: 26051499
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
[TBL] [Abstract][Full Text] [Related]
14. Impact of concomitant chemotherapy on outcomes of radiation therapy for head-and-neck cancer: a population-based study.
Gupta S; Kong W; Booth CM; Mackillop WJ
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):115-21. PubMed ID: 24331657
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Franchin G; Vaccher E; Gobitti C; Minatel E; Politi D; Talamini R; Di Gennaro G; Savignano G; Trovò MG; Tirelli U; Barzan L
Oral Oncol; 2005 May; 41(5):526-33. PubMed ID: 15878759
[TBL] [Abstract][Full Text] [Related]
16. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
17. Frequency of esophageal stenosis after simultaneous modulated accelerated radiation therapy and chemotherapy for head and neck cancer.
Lawson JD; Otto K; Grist W; Johnstone PA
Am J Otolaryngol; 2008; 29(1):13-9. PubMed ID: 18061826
[TBL] [Abstract][Full Text] [Related]
18. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
20. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
